Lord, Abbett & Co’s Medpace MEDP Stock Holding History

Lord, Abbett & Co’s Portfolio MEDP Stock Details MEDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,843	Closed	-$2.1M	–	573
2023 Q4	$2.1M	Sell	6,843 -107,745	-94%	-$29.1M	0.01%	499
2023 Q3	$27.7M	Buy	114,588 +99,949	+683%	+$25.6M	0.1%	268
2023 Q2	$3.52M	Buy	+14,639	New	+$3.04M	0.01%	504
2023 Q1	–	Sell	-109,000	Closed	-$23.2M	–	606
2022 Q4	$23.2M	Buy	+109,000	New	+$21.8M	0.08%	324

Other funds holding MEDP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Lord, Abbett & Co's MEDP Position: Q1 2024 in Review

Lord, Abbett & Co sold out of Medpace (MEDP) in Q1 2024, closing a stake of 6,843 shares — an estimated $2.1M sold.

Lord, Abbett & Co first reported a position in MEDP in Q4 2022 and held it in 4 quarters. The position peaked at $27.7M in Q3 2023. 597 funds tracked by Wall St. Rank hold MEDP as of Q1 2024.

Lord, Abbett & Co reported no remaining Medpace position as of Q1 2024 after selling out during the quarter.
Lord, Abbett & Co sold 6,843 Medpace shares in Q1 2024, an estimated $2.1M.
Lord, Abbett & Co first reported a position in Medpace in Q4 2022 and held it in 4 quarters.
Lord, Abbett & Co's Medpace position peaked at $27.7M in Q3 2023.
597 funds tracked by Wall St. Rank held Medpace as of Q1 2024.

Based on Lord, Abbett & Co's 13F filing for Q1 2024, filed 9 May 2024.